Robaxin: Targeted Muscle Spasm Relief for Enhanced Mobility
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.03 | $40.26 (0%) | 🛒 Add to cart |
| 20 | $2.26 | $80.51 $45.29 (44%) | 🛒 Add to cart |
| 30 | $1.68 | $120.77 $50.32 (58%) | 🛒 Add to cart |
| 60 | $0.92 | $241.54 $55.35 (77%) | 🛒 Add to cart |
| 90 | $0.67 | $362.31 $60.38 (83%) | 🛒 Add to cart |
| 120 | $0.59 | $483.08 $70.45 (85%) | 🛒 Add to cart |
| 180 | $0.50 | $724.62 $90.58 (88%) | 🛒 Add to cart |
| 270 | $0.45 | $1086.93 $120.77 (89%) | 🛒 Add to cart |
| 360 | $0.42
Best per pill | $1449.23 $150.96 (90%) | 🛒 Add to cart |
Synonyms | |||
Robaxin (methocarbamol) is a centrally acting skeletal muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions. It is used as an adjunct to rest, physical therapy, and other measures for the relief of muscle spasm. This agent works by depressing polysynaptic spinal reflexes and possesses sedative properties, making it a valuable tool in comprehensive pain management protocols. Its efficacy is well-documented in clinical settings for providing symptomatic relief, thereby facilitating rehabilitation and improving patient quality of life during recovery.
Features
- Active ingredient: Methocarbamol
- Available in 500 mg and 750 mg oral tablets
- Also available in injectable form for hospital use (Robaxin Injectable)
- Onset of action: Oral administration typically provides relief within 30 minutes
- Duration of effect: Approximately 4-6 hours per dose
- Prescription-only medication in most jurisdictions
- White, round, film-coated tablets for easy swallowing
Benefits
- Provides rapid relief from acute musculoskeletal pain and spasm
- Reduces muscle stiffness, allowing for improved range of motion
- Facilitates participation in physical therapy and rehabilitation programs
- Helps break the pain-spasm-pain cycle through central nervous system action
- May decrease the need for additional analgesic medications when used as part of a comprehensive treatment plan
- Supports faster recovery from musculoskeletal injuries by enabling earlier mobilization
Common use
Robaxin is primarily prescribed for the management of acute musculoskeletal conditions accompanied by muscle spasm. Common indications include back pain, muscle strains, sprains, and other traumatic injuries. It is frequently used post-operatively in orthopedic procedures to manage muscle spasm and discomfort. The medication is typically prescribed for short-term use (usually not exceeding 2-3 weeks) as part of a comprehensive treatment approach that includes rest, physical therapy, and other conservative measures. Healthcare providers may also prescribe Robaxin for certain neurological conditions involving spasticity, though this represents an off-label use.
Dosage and direction
The recommended adult dosage of Robaxin tablets is 1500 mg four times daily for the first 48-72 hours of treatment (up to 8 grams per day may be used in severe conditions). For maintenance therapy, the dosage may be reduced to 1000 mg four times daily, or 1500 mg three times daily. Tablets should be swallowed whole with a full glass of water and may be taken with or without food. The dosage for Robaxin Injectable is administered by healthcare professionals only, typically at an initial dose of 1-3 grams per day, not to exceed 3 grams for more than 3 consecutive days. Treatment duration should not exceed 2-3 weeks unless specifically directed by a physician.
Precautions
Patients should exercise caution when operating machinery or driving, as Robaxin may cause drowsiness, dizziness, or blurred vision. Alcohol consumption should be avoided during treatment, as it may enhance the sedative effects. Use with caution in patients with hepatic impairment, as the drug is metabolized in the liver. Elderly patients may be more sensitive to the effects of Robaxin and typically require lower doses. Patients should be monitored for signs of allergic reactions, including skin rash or urticaria. Those with a history of drug abuse or dependence should use this medication with particular caution due to its potential for CNS depression.
Contraindications
Robaxin is contraindicated in patients with known hypersensitivity to methocarbamol or any component of the formulation. It should not be used in patients with renal impairment, as the drug and its metabolites are excreted renally. The injectable form is contraindicated in patients with epilepsy or other seizure disorders. Concomitant use with other CNS depressants is generally contraindicated unless carefully monitored by a healthcare provider. The medication is not recommended during pregnancy unless the potential benefits outweigh the risks, and should be used with caution in breastfeeding women.
Possible side effect
Common side effects include dizziness, drowsiness, nausea, and blurred vision, which typically diminish with continued use. Less frequently, patients may experience headache, metallic taste, fever, or allergic skin reactions. Rare but serious side effects include anaphylaxis, leukopenia, and syncope. The injectable form may cause pain at the injection site, flushing, or hypotension. Patients should report any persistent or severe side effects to their healthcare provider immediately. Most adverse effects are dose-related and may be managed through dosage adjustment.
Drug interaction
Robaxin may potentiate the effects of other CNS depressants including alcohol, benzodiazepines, opioids, and sedative-hypnotics. Concurrent use with MAO inhibitors may enhance CNS depression. It may increase the effects of warfarin and other oral anticoagulants, requiring closer monitoring of coagulation parameters. The metabolism of methocarbamol may be affected by drugs that induce or inhibit hepatic enzymes. Concomitant use with anticholinergic agents may enhance cognitive impairment. Healthcare providers should review all medications, including over-the-counter products and herbal supplements, before prescribing Robaxin.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never double the dose to make up for a missed one. If multiple doses are missed or there is uncertainty about dosing, patients should contact their healthcare provider for guidance. Consistent dosing is important for maintaining therapeutic levels and optimal symptom control.
Overdose
Symptoms of Robaxin overdose may include severe drowsiness, nausea, vomiting, syncope, hypotension, respiratory depression, and coma. In severe cases, seizures and cardiac arrest may occur. Management involves supportive care, including airway protection and monitoring of vital signs. Gastric lavage may be considered if presentation is early. There is no specific antidote for methocarbamol overdose. Hemodialysis is not effective due to high protein binding. Treatment should focus on symptomatic management and supportive measures in a monitored healthcare setting.
Storage
Robaxin tablets should be stored at controlled room temperature (20-25°C or 68-77°F) in their original container, protected from light and moisture. The medication should be kept out of reach of children and pets. Unused medication should be properly disposed of according to local regulations once treatment is completed or if the product has expired. Do not store in bathrooms or other areas with high humidity. The injectable form requires specific storage conditions as directed by the manufacturer and healthcare facility protocols.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Robaxin is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to medication may vary, and proper diagnosis and treatment planning should be established by a physician. Patients should not adjust dosage or discontinue medication without consulting their healthcare provider. The complete prescribing information should be reviewed before initiating therapy.
Reviews
Clinical studies demonstrate that Robaxin provides effective relief for acute musculoskeletal spasm in approximately 70-80% of patients. Many healthcare providers report satisfactory results when used as part of a comprehensive treatment plan. Patients typically note improvement in mobility and reduction in pain within the first few days of treatment. Some reviews mention drowsiness as a limiting factor, particularly during the initial phase of therapy. The medication is generally well-tolerated when used as directed for appropriate indications. Long-term satisfaction rates are highest when combined with physical therapy and other rehabilitative measures.